Screening for gynaecological cancers

European Journal of Surgical Oncology

Volumn 32, Issue 8, 2006, Pages 818-824

  Sharma, A ^a   Menon, U ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cervical cancer; Endometrial cancer; Gynaecological malignancy; Ovarian neoplasm; Screening

Indexed keywords

CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; INHIBIN; KALLIKREIN; LYSOPHOSPHATIDIC ACID; OSTEOPONTIN; PROSTASIN; TELOMERASE; VIRUS DNA;

ANTIGEN DETECTION; ARTICLE; ARTIFICIAL INTELLIGENCE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DNA DETERMINATION; DOPPLER ECHOGRAPHY; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FEMALE; GYNECOLOGIC CANCER; HUMAN; INFORMATION PROCESSING; MASS SCREENING; MEDLINE; OVARY CANCER; PAPANICOLAOU TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; RARE DISEASE; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE TUBE CARCINOMA; VAGINA CANCER; VULVA CANCER; WART VIRUS;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MASS SCREENING;

EID: 33749142544     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.034     Document Type: Article

References (76)

1. What is screening?. http://www.nsc.nhs.uk/
2. Cervical screening has reduced incidence of cancer and mortality. BMJ 318 7188 (1999)
3. Sasieni P., and Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 318 7193 (1999) 1244-1245
4. McNeeley Jr. S.G. New cervical cancer screening techniques. Am J Obstet Gynecol 189 4 Suppl (2003) S40-S41
5. Monsonego J., Autillo-Touati A., Bergeron C., et al. Liquid phase cytology in the primary screening for cervical cancer: a multicenter study. Gynecol Obstet Fertil 29 11 (2001) 799-807
6. NICE. Full guidance on the use of liquid-based cytology for cervical screening (review), 2003.
7. 2003/54 NICE guidance on liquid based cytology contributes to modernisation of cervical screening services for women (2003), NICE
8. Moss S., Gray A., Legood R., and Henstock E. First report to the department of health on evaluation of LBC (2002)
9. Menon U., and Jacobs I.J. Tumor markers and screening. 4th ed. (2003)
10. Shvartsman H.S., Lu K.H., Lee J., et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90 1 (2003) 44-50
11. Ni X., Zhang W., Huang K.C., et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91 4 (2004) 725-731
12. Lorincz A.T. Screening for cervical cancer: new alternatives and research. Salud Publica Mex 45 Suppl 3 (2003) S376-S387
13. Nieminen P., Vuorma S., Viikki M., Hakama M., and Anttila A. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. BJOG 111 8 (2004) 842-848
14. Petry K.U., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88 10 (2003) 1570-1577
15. Franco E.L. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 31 (2003) 89-96
16. Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 9399 (2003) 1871-1876
17. Cuzick J., Szarewski A., Terry G., et al. Human papillomavirus testing in primary cervical screening. Lancet 345 8964 (1995) 1533-1536
18. Sasieni P.D. Human papillomavirus screening and cervical cancer prevention. J Am Med Womens Assoc 55 4 (2000) 216-219
19. Schiffman M., and Castle P.E. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 127 8 (2003) 930-934
20. Baay M.F., Smits E., Tjalma W.A., et al. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 108 2 (2004) 258-261
21. Franco E.L. Are we ready for a paradigm change in cervical cancer screening?. Lancet 362 9399 (2003) 1866-1867
22. Goldie S.J., Kim J.J., and Wright T.C. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 103 4 (2004) 619-631
23. Holmes J., Hemmett L., and Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ 6 1 (2005) 30-37
24. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 6 (2002) 342-362
25. Human Papilloma Virus (HPV). http://www.cancerscreening.nhs.uk/cervical/hpv.html
26. Schiffman M., and Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 127 8 (2003) 946-949
27. Cox J.T. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors. Arch Pathol Lab Med 127 8 (2003) 950-958
28. Cuzick J., Sasieni P., Davies P., et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 83 5 (2000) 561-565
29. Almog B., Gamzu R., Bornstein J., et al. Clinical and economic benefit of HPV-load testing in follow-up and management of women postcone biopsy for CIN2-3. Br J Cancer 89 1 (2003) 109-112
30. Schiffman M., Khan M.J., Solomon D., et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 97 2 (2005) 147-150
31. Finan R.R., Irani-Hakime N., Tamim H., and Almawi W.Y. Validity of vaginal testing in detecting human papillomavirus (HPV) genotypes. J Clin Virol 19 3 (2000) 163-168
32. Palmisano M.E., Gaffga A.M., Daigle J., et al. Detection of human papillomavirus DNA in self-administered vaginal swabs as compared to cervical swabs. Int J STD AIDS 14 8 (2003) 560-567
33. Gravitt P.E., Lacey Jr. J.V., Brinton L.A., et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev 10 2 (2001) 95-100
34. Harper D.M., Hildesheim A., Cobb J.L., Greenberg M., Vaught J., and Lorincz A.T. Collection devices for human papillomavirus. J Fam Pract 48 7 (1999) 531-535
35. Reddy V.G., Khanna N., Jain S.K., Das B.C., and Singh N. Telomerase - a molecular marker for cervical cancer screening. Int J Gynecol Cancer 11 2 (2001) 100-106
36. Ngan H.Y., Cheung A.N., Liu S.S., Liu K.L., and Tsao S.W. Telomerase assay and HPV 16/18 typing as adjunct to conventional cytological cervical cancer screening. Tumour Biol 23 2 (2002) 87-92
37. Wesley R., Sankaranarayanan R., Mathew B., et al. Evaluation of visual inspection as a screening test for cervical cancer. Br J Cancer 75 3 (1997) 436-440
38. Wright Jr. T.C., Denny L., Kuhn L., and Goldie S. Use of visual screening methods for cervical cancer screening. Obstet Gynecol Clin North Am 29 4 (2002) 701-734
39. Ferris D.G., Payne P., Frisch L.E., Milner F.H., diPaola F.M., and Petry L.J. Cervicography: adjunctive cervical cancer screening by primary care clinicians. J Fam Pract 37 2 (1993) 158-164
40. Suba E.J., and Raab S.S. Direct visual inspection for cervical cancer screening. Cancer 101 10 (2004) 2365 [author reply 2366]
41. Gaffikin L., Lauterbach M., and Blumenthal P.D. Performance of visual inspection with acetic acid for cervical cancer screening: a qualitative summary of evidence to date. Obstet Gynecol Surv 58 8 (2003) 543-550
42. Belinson J.L., Pretorius R.G., Zhang W.H., Wu L.Y., Qiao Y.L., and Elson P. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 98 3 (2001) 441-444
43. Menon U., and Jacobs I.J. Tumor markers. 3rd ed. (2000), LWW
44. Fritsche H.A., and Bast R.C. CA 125 in ovarian cancer: advances and controversy. Clin Chem 44 7 (1998) 1379-1380
45. Jacobs I., Davies A.P., Bridges J., et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 306 6884 (1993) 1030-1034
46. Menon U., Talaat A., Rosenthal A.N., et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 107 2 (2000) 165-169
47. Skates S.J., Menon U., MacDonald N., et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21 Suppl. 10 (2003) 206-210
48. Ardekani A.M., Liotta L.A., and Petricoin III E.F. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2 4 (2002) 312-320
49. Bandera C.A., Ye B., and Mok S.C. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 15 1 (2003) 51-55
50. Markman M., Belinson J., Webster K., et al. Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. Oncology 66 5 (2004) 343-346
51. Ahmed N., Oliva K., Rice G.E., and Quinn M.A. Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res 10 7 (2004) 2415-2420
52. Chappuis P.O., Narod S.A., and Foulkes W.D. Screening for ovarian cancer. Lancet 354 9177 (1999) 509-510
53. Diamandis E.P., Scorilas A., Fracchioli S., et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 21 6 (2003) 1035-1043
54. Granberg S., Wikland M., and Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 35 2 (1989) 139-144
55. Carter J.R., Lau M., Fowler J.M., Carlson J.W., Carson L.F., and Twiggs L.B. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol 172 3 (1995) 901-907
56. Cohen L.S., Escobar P.F., Scharm C., Glimco B., and Fishman D.A. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 82 1 (2001) 40-48
57. Menon U. Ovarian cancer screening. CMAJ 171 4 (2004) 323-324
58. Andriole G.L., Reding D., Hayes R.B., Prorok P.C., and Gohagan J.K. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol 22 4 (2004) 358-361
59. Hayes R.B., Reding D., Kopp W., et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21 Suppl. 6 (2000) 349S-355S
60. Rebbeck T.R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38 Suppl. 6 (2002) S15-S17
61. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 21 (2002) 1616-1622
62. Bell R., Petticrew M., Luengo S., and Sheldon T.A. Screening for ovarian cancer: a systematic review. Health Technol Assess 2 2 (1998) i-iv 1-84
63. Baiocchi G., and Gilardi G. Endometrial carcinoma: an increasing neoplasm. Screening and early diagnosis: proposal for a protocol. Minerva Ginecol 49 4 (1997) 147-152
64. Chlebowski R.T., Collyar D.E., Somerfield M.R., and Pfister D.G. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17 6 (1999) 1939-1955
65. ACOG committee opinion: tamoxifen and endometrial cancer. Int J Gynaecol Obstet 73 1 (2001) 77-79
66. Berliere M., Charles A., Galant C., and Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 91 1 (1998) 40-44
67. Barakat R.R. Benign and hyperplastic endometrial changes associated with tamoxifen use. Oncology (Huntingt) 11 2 Suppl. 1 (1997) 35-37
68. Barakat R.R. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J Clin Oncol 17 7 (1999) 1967-1968
69. Huang D., Chen C., Sun W., Strom C.M., and Bender R.A. High-throughput gene sequencing assay development for hereditary nonpolyposis colon cancer. Clin Colorectal Cancer 4 4 (2004) 275-279
70. Chung L., Broaddus R., Crozier M., Luthraa R., Levenback C., and Lu K. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 102 5 Pt 2 (2003) 1152-1155
71. Boks D.E., Trujillo A.P., Voogd A.C., Morreau H., Kenter G.G., and Vasen H.F. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 102 2 (2002) 198-200
72. Barik S., and Tidy J. Screening for endometrial cancer in asymptomatic postmenopausal women with conventional and colour Doppler sonography. Br J Obstet Gynaecol 106 11 (1999) 1229-1230
73. Zygmunt A., Markowska J., and Fischer N. Significance of tissue polypeptide specific antigen (TPS) in diagnosis and monitoring of treatment in ovarian cancer. Eur J Gynaecol Oncol 19 5 (1998) 484-486
74. Al-Jehani R.M., Jeyarajah A.R., Hagen B., Hogdall E.V., Oram D.H., and Jacobs I.J. Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. J Natl Cancer Inst 90 7 (1998) 540-542
75. Yokoyama Y., Takahashi Y., Morishita S., Hashimoto M., Niwa K., and Tamaya T. Telomerase activity in the human endometrium throughout the menstrual cycle. Mol Hum Reprod 4 2 (1998) 173-177
76. Zheng P.S., Iwasaka T., Yamasaki F., et al. Telomerase activity in gynecologic tumors. Gynecol Oncol 64 1 (1997) 171-175